TABLE 27Measures of cognition in included studies: memantine vs placebo

StudySubgroupOutcomeTypeMemantinePlacebop-value
nMean (SD)nMean (SD)
Van Dyck et al. (2007)143LOCF analysisSIB – 24 weeksMC170−2 (13)165−2.5 (12.8)0.616a
OC populationSIB – 4 weeksMC1670.875 (7.43)b164−0.3 (6.4)b0.146a
SIB – 8 weeks1582.08 (7.86)b1550.375 (7.16)b0.064a
SIB – 12 weeks1461.65 (9.06)b150−0.825 (8.27)b0.008a
SIB – 18 weeks1400 (8.28)b139−2.12 (9.14)b0.065a
SIB – 24 weeks131−1.8 (12.6)126−2.4 (13.5)0.617a

MC, mean change.

a

Analysis of covariance (ANCOVA) (treatment group and centre as main effects; baseline score as covariate).

b

Estimated from figure.

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.